Study shows low rate of late lumen loss with bioresorbable DESolve device

May 21, 2013

21 May 2013, Paris, France: The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013 today.

DESolve (Elixir Medical Corporation) is the first bioresorbable PLLA-based polymer scaffold that releases novolimus, a major metabolite of sirolimus. "The degradation time is about one year," explained the lead study author Alexandre Abizaid, Director of Interventional Cardiology at Institute Dante Pazzanese de Cardiologia, São Paulo, Brazil. He added, "One of the most attractive features, which we don't see with most bioresorbable scaffolds, is that this device shows significant increase in vessel scaffold and luminal area at six months."

The DESolve Nx trial treated target lesions in 126 patients with single de novo coronary artery lesions with the DESolve device. Results showed the primary endpoint of in-stent late lumen loss was 0.21mm (+0.34) at six months. Major adverse cardiac events occurred in 3.25% of patients, including one cardiac death. Acute recoil occurred in 6.6% of patients at six months.

Stents and vessels were assessed by IVUS in a subset of 40 patients. "There was a clearly significant increase in vessel area," Abizaid reported. Mean vessel area increased by 16.8% at six months (p<0.001), while mean scaffold area increased by 15.7% (p<0.001) and mean lumen area by 9.0% (p<0.001). "We don't usually see this improvement until two years," he noted. Serial optical coherence tomography (OCT) analysis in 38 patients demonstrated a 16.9% increase in mean scaffold area (p<0.001) after six months. Nearly 99% of struts were covered by this time point.

Summing up the findings, Abizaid concluded, "The DESolve Nx trial was successful in demonstrating the safety and efficacy of the DESolve Scaffold. In terms of acute performance, there was a high rate of device deliverability and acute recoil was low. Efficacy results showed low late lumen loss at six months and safety was also good, with a low six-month MACE rate and high strut coverage." He added, "What really impressed me was to see an increase in scaffold and lumen areas indicating early vessel restoration at six months. We saw results at six months that we see with most scaffolds at two to three years."

Commenting on the study findings, Adnan Kastrati, Deputy Director of Cardiovascular Diseases at the German Heart Centre of the State of Bavaria, Munich, Germany, said, "Bioresorbable drug-eluting scaffolds are emerging as the dominant device of the future for percutaneous coronary interventions. The results shown today with the DESolve scaffold eluting novolimus make interventional cardiologists richer in treatment options. Different biopolymer resorption kinetics and antiproliferative drugs may better serve individualisation of PCI treatment to patients' needs." But he cautioned, "The promising results shown with bioresorbable drug-eluting scaffolds so far need corroboration in larger patient cohorts followed for a longer period. Last, but not at least, available devices still need design improvement before offering their advantages to the majority of complex lesions we are currently treating."
-end-


European Society of Cardiology

Related Safety Articles from Brightsurf:

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

How EU safety legislation has affected UK vapers
New research shows that vapers have been largely reassured by recent EU regulations, but some have been pushed to the black market for stronger hits.

Tunnel fire safety
With only minutes to respond, fire education really counts.

New study supports the safety of varenicline
A real-world study of over 600,000 adult participants without a history of depression has found that the stop-smoking medication varenicline (marketed as Chantix and Champix) does not appear to be associated with an increased risk of cardiovascular or neuropsychiatric hospitalization compared with nicotine replacement therapy (NRT).

Advancing frozen food safety: Cornell develops novel food safety assessment tool
New research funded by the Frozen Food Foundation developed a modeling tool to assist the frozen food industry with understanding and managing listeriosis risks.

'Safety signals' may help slow down anxiety
For as many as one in three people, life events or situations that pose no real danger can spark a disabling fear, a hallmark of anxiety and stress-related disorders.

UQ researcher carving a new path for skier safety
A spectacular stack on a ski slope in Canada has led to a University of Queensland researcher determining a simple modification that could improve skier safety on the snow.

Nanomaterial safety on a nano budget
A Rice University laboratory develops and shares a low-cost method to safely handle the transfer of bulk carbon nanotubes and other nanomaterials.

Drexel-developed safety climate scale helps fire departments reach safety goals
A new safety scale, that effectively measures the safety climate of a fire department, has been developed by researchers from Drexel's Dornsife School of Public Health, according to a paper published today in the journal Safety Science.

Safety of overlapping surgeries
Overlapping surgeries, in which more than one procedure is performed by the same surgeon working in different operating rooms, have raised concerns about potential adverse outcomes.

Read More: Safety News and Safety Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.